30650-90-9

Usage

Uses

Used in Perfumery and Flavoring Industry:
ETHYL 3-METHYL-4-NITROBENZOATE is used as a fragrance ingredient and flavoring agent for its pleasant odor, enhancing the scent and taste profiles of various products.
Used in Pharmaceutical Industry:
ETHYL 3-METHYL-4-NITROBENZOATE is utilized in the production of pharmaceuticals, serving as a key intermediate in the synthesis of various medicinal compounds.
Used in Organic Synthesis:
As an intermediate in organic synthesis, ETHYL 3-METHYL-4-NITROBENZOATE plays a crucial role in the development of new chemical entities and the modification of existing ones, contributing to the advancement of chemical research and product innovation.

InChI:InChI=1/C10H11NO4/c1-3-15-10(12)8-4-5-9(11(13)14)7(2)6-8/h4-6H,3H2,1-2H3

Upstream product

• 64-17-5 ethanol 
• 3113-71-1 3-methyl-4-nitrobenzoic acid 
• 75-03-6 ethyl iodide 

Downstream Products

• 40800-65-5 1-amino-2-methylbenzene-4-carboxylic acid ethyl ester 
• 86400-51-3 3-bromomethyl-4-nitro-benzoic acid ethyl ester 
• 103039-34-5 5-methyl-2,4-dinitrobenzoic acid ethyl ester 
• 840531-19-3 ethyl 3-[(3-cyanophenoxy)methyl]-4-nitrobenzoate 
• 840531-22-8 ethyl 3-[(3-cyanophenoxy)methyl]-4-{[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]amino}benzoate 
• 840531-38-6 ethyl 3-({3-[amino(imino)methyl]phenoxy}methyl)-4-{[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]amino}benzoate 
• 412317-99-8 3-hydroxymethyl-4-nitrobenzoic acid ethyl ester 
• 412318-00-4 3-hydroxymethyl-4-nitrobenzoic acid allyl ester 
• 412318-01-5 2-nitro-5-(allyloxycarbonyl)benzyl 4-nitrophenyl carbonate 
• 27715-62-4 5-methyl-2,4-dinitrobenzamide 
• 174311-74-1 6-amino-1H-indole-5-carboxylic acid ethyl ester 
• 174311-76-3 (E)-5-<2-(dimethylamino)ethenyl>-2,4-dinitrobenzamide 
• 174311-73-0 (E)-5-<2-(dimethylamino)ethenyl>-2,4-dinitrobenzoic acid ethyl ester 
• 171179-60-5 N-<(dimethylamino)methylene>-(E)-5-<2-(dimethylamino)ethenyl>-2,4-dinitrobenzamide 

Relevant academic research and scientific papers

Oxygen-Tolerant H2 Production by [FeFe]-H2ase Active Site Mimics Aided by Second Sphere Proton Shuttle

The instability of [FeFe]-H2ases and their biomimetics toward O2 renders them inefficient to implement in practical H2 generation (HER). Previous investigations on synthetic models as well as natural enzymes proved that re

Deuterated methyl telmisartan as well as preparation method and application thereof

The invention belongs to the field of organic and pharmaceutical synthesis, and discloses deuterated methyl telmisartan as well as a preparation method and application thereof. The method adopts 3-methyl-4-nitrobenzoic acid as a raw material, adopts deute

Synthesis of symmetric diester-functionalised Troeger's base analogues

The yields of ester-functionalised Troeger's base analogues are dramatically improved by incorporating an electron-donating group on the aromatic ring and/or enhancing solubil- ity of the aniline unit. In addition to 2,8-diester compounds, 1,7-, 3,9- and 4,10-diester-functionalised Troeger's base analogues have been prepared for the first time.

Effect of the ortho modification of azobenzene on the photoregulatory efficiency of DNA hybridization and the thermal stability of its eis form

We synthesized various azobenzenes methylated at their ortho positions with respect to the azo bond for more effective photoregulation of DNA hybridization. Photoregulatory efficiency, evaluated from the change of T m (ΔTm) induced by trans-cis isomerization, was significantly improved for all ortho-modified azobenzenes compared with non-modified azobenzene due to the more stabilized trans form and the more destabilized cis form. Among the synthesized azobenzenes, 4-carboxy-2',6'- dimethylazobenzene (2',6'-Me-Azo), in which two ortho positions of the distal benzene ring with respect to carboxyl group were methylated, exhibited the largest ΔTm, whereas the newly synthesized 2,6-Me-Azo (4-carboxy-2,6- dimethylazobenzene), which possesses two methyl groups on the two ortho positions of the other benzene ring, showed moderate improvement of ΔTm. Both NMR spectroscopic analysis and computer modeling revealed that the two methyl groups on 2',6'-Me-Azo were located near the imino protons of adjacent base pairs; these stabilized the DNA duplex by stacking interactions in the trans form and destabilized the DNA duplex by steric hindrance in the cis form. In addition, the thermal stability of cis-2',6'-Me-Azo was also greatly improved, but not that of cis2,6-Me-Azo. Solvent effects on the half-life of the cis form demonstrated that cis-to-trans isomerization of all the modified azobenzenes proceeded through an inversion route. Improved thermal stability of 2',6'-Me-Azo but not 2,6-Me-Azo in the eis form was attributed to the retardation of the inversion process due to steric hindrance between lone pair electrons of the π orbital of the nitrogen atom and the methyl group on the distal benzene ring.

Integrin antagonists

This invention relates to novel heterocycles which are useful as antagonists of the αvβ3 integrin, the α2bβ3 integrin, and related cell surface adhesive protein receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.

Integrin receptor antagonists

This invention relates to novel heterocycles including 3-?1-?3-(imidazolin-2-ylamino)propyl!indazol-5-ylcarbonylamino!-2-(benzyloxycarbonylamino)propionic acid, which are useful as antagonists of the αv β3 integrin and related cell surface adhesive protein receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.